Promising new agents in early clinical development for the treatment of CCA include compounds that target the JAK/STAT pathway, the Wnt/β-catenin signaling and the Hedgehog signaling (HH) pathways. This evidence concerns the gene SOAT1 and cholangiocarcinoma.